Paradigm Biocapital Advisors LP
NEW YORK, NY
$5.3bn in 28 US stocks at the end of 30 June 2026. The top 10 are 75.2% of the money. It changed about 36.3% of the portfolio this quarter.
Value
$5.3bn
Stocks
28
Top 10 share
75.2%
Turnover
36.3%
What changed this quarter
New
Bought for the first time this quarter.
- Alnylam PharmaceuticalsALNY2.7% of the fund
- MBX BiosciencesMBX2.6% of the fund
- Jade BiosciencesJBIO1.2% of the fund
- Achieve Life SciencesACHV0.6% of the fund
- MapLight TherapeuticsMPLT0.5% of the fund
- KardiganKARD0.4% of the fund
- Editas MedicineEDIT0.3% of the fund
Added
Bought more of a stock they already held.
- Nuvalent13.7% of the fund+11%
- Edgewise TherapeuticsEWTX7.8% of the fund+39%
- Genmab A/SGMAB6.8% of the fund+65%
- Spyre TherapeuticsSYRE6.4% of the fund+96%
- Apogee TherapeuticsAPGE3.9% of the fund+17%
- Tango TherapeuticsTNGX3.7% of the fund+59%
- Belite BIOBLTE3.6% of the fund+11%
- Tarsus PharmaceuticalsTARS3.3% of the fund+8%
- InsmedINSM2.6% of the fund+6%
- Viridian TherapeuticsVRDN2.3% of the fund+114%
- Olema PharmaceuticalsOLMA2.0% of the fund+8%
- Assembly BiosciencesASMB0.8% of the fund+134%
Cut
Sold some of their stake.
- Revolution MedicinesRVMD22.3% of the fund-4%
- Oruka TherapeuticsORKA3.8% of the fund-8%
- ErascaERAS3.3% of the fund-8%
- VaxcytePCVX2.3% of the fund-56%
- Tyra BiosciencesTYRA1.1% of the fund-11%
- EyePointEYPT0.8% of the fund-8%
- Lexeo TherapeuticsLXEO0.4% of the fund-32%
Sold out
Sold their entire stake.
- Arcellx-100%
- Centessa Pharmaceuticals-100%
- Terns Pharmaceuticals-100%
- CytokineticsCYTK-100%
- Abivax SAABVX-100%
- Maze TherapeuticsMAZE-100%
- Scholar Rock HoldingSRRK-100%
- Mirum PharmaceuticalsMIRM-100%
- VeradermicsMANE-100%
- UroGen PharmaURGN-100%
- Structure TherapeuticsGPCR-100%
- Oric PharmaceuticalsORIC-100%
- BridgeBio Oncology TherapeuticsBBOT-100%
- Kalaris TherapeuticsKLRS-100%
Holdings
- Nuvalent
- Share
- 13.7%
- Value
- $732m
- Shares
- 5,924,433
+11%
- Genmab A/SGMAB
- Share
- 6.8%
- Value
- $361m
- Shares
- 13,133,131
+65%
- Apogee TherapeuticsAPGE
- Share
- 3.9%
- Value
- $209m
- Shares
- 1,576,385
+17%
- Belite BIOBLTE
- Share
- 3.6%
- Value
- $190m
- Shares
- 1,232,877
+11%
- KardiganKARD
- Share
- 0.4%
- Value
- $21m
- Shares
- 900,000
New
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Revolution MedicinesRVMD | 22.3% | $1.2bn | 6,361,323 | -4% |
| Nuvalent | 13.7% | $732m | 5,924,433 | +11% |
| Edgewise TherapeuticsEWTX | 7.8% | $415m | 10,215,455 | +39% |
| Genmab A/SGMAB | 6.8% | $361m | 13,133,131 | +65% |
| Spyre TherapeuticsSYRE | 6.4% | $341m | 3,840,778 | +96% |
| Apogee TherapeuticsAPGE | 3.9% | $209m | 1,576,385 | +17% |
| Oruka TherapeuticsORKA | 3.8% | $204m | 2,144,526 | -8% |
| Tango TherapeuticsTNGX | 3.7% | $199m | 6,357,523 | +59% |
| Belite BIOBLTE | 3.6% | $190m | 1,232,877 | +11% |
| ErascaERAS | 3.3% | $175m | 9,550,000 | -8% |
| Tarsus PharmaceuticalsTARS | 3.3% | $175m | 2,775,649 | +8% |
| Alnylam PharmaceuticalsALNY | 2.7% | $144m | 480,000 | New |
| InsmedINSM | 2.6% | $141m | 1,325,977 | +6% |
| MBX BiosciencesMBX | 2.6% | $138m | 2,508,015 | New |
| VaxcytePCVX | 2.3% | $124m | 2,127,852 | -56% |
| Viridian TherapeuticsVRDN | 2.3% | $124m | 6,723,788 | +114% |
| Olema PharmaceuticalsOLMA | 2.0% | $108m | 8,670,576 | +8% |
| Jade BiosciencesJBIO | 1.2% | $63m | 2,857,405 | New |
| Tyra BiosciencesTYRA | 1.1% | $58m | 1,828,607 | -11% |
| Assembly BiosciencesASMB | 0.8% | $43m | 1,553,748 | +134% |
| EyePointEYPT | 0.8% | $41m | 2,890,397 | -8% |
| Achieve Life SciencesACHV | 0.6% | $32m | 4,951,856 | New |
| Vor BiopharmaVOR | 0.6% | $32m | 1,750,000 | Held |
| MapLight TherapeuticsMPLT | 0.5% | $25m | 685,852 | New |
| KardiganKARD | 0.4% | $21m | 900,000 | New |
| Lexeo TherapeuticsLXEO | 0.4% | $19m | 4,175,382 | -32% |
| Editas MedicineEDIT | 0.3% | $18m | 5,586,625 | New |
| InventivaIVA | 0.3% | $15m | 4,000,000 | Held |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 128.0% since 30 June 2025.
Where the money is
Health care76.0%
Other24.0%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.